Claims for Patent: 8,748,459

Summary for Patent: 8,748,459

Title:	Pyridinoylpiperidines as 5-HT.sub.1F agonists
Abstract:	The present invention relates to compounds of formula I: ##STR00001## or pharmaceutically acceptable acid addition salts thereof, where; R.sup.1 is C.sub.1-C.sub.6 alkyl, substituted C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, substituted C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, substituted C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R.sup.2 is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.6 cycloalkyl-C.sub.1-C.sub.3 alkyl, or a group of formula II ##STR00002## R.sup.3 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.4 is hydrogen, halo, or C.sub.1-C.sub.3 alkyl; R.sup.5 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.6 is hydrogen or C.sub.1-C.sub.6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT.sub.lF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
Inventor(s):	Cohen; Michael Philip (Indianapolis, IN), Kohlman; Daniel Timothy (Camby, IN), Liang; Sidney Xi (Bethany, CT), Victor; Frantz (Indianapolis, IN), Xu; Yao-Chang (Fishers, IN), Ying; Bai-Ping (Sunnyvale, CA), Zacherl; DeAnna Piatt (Noblesville, IN), Zhang; Deyi (Carmel, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	13/363,895
Patent Claims:	1. A method for the treatment of migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-b- enzamide or a pharmaceutically acceptable acid addition salt thereof. 2. A method for the treatment of migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-b- enzamide hydrochloride salt. 3. A method for the treatment of migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-b- enzamide hydrochloride salt.